News | Cardiac Resynchronization Therapy Devices (CRT) | July 06, 2017

New Data Reveal Medtronic CRT Devices Improve Therapy Delivery and Reduce Healthcare Costs

Data presented at EUROPACE 2017 reinforce cost and outcome benefits of exclusive EffectivCRT and AdaptivCRT algorithms, along with improved device longevity

New Data Reveal Medtronic CRT Devices Improve Therapy Delivery and Reduce Healthcare Costs

July 6, 2017 — New data showed use of Medtronic’s cardiac resynchronization therapy (CRT) devices with its proprietary AdaptivCRT and EffectiveCRT algorithms results in lower healthcare system costs, and improves therapy delivery in heart failure patients who also have atrial fibrillation (AF). The results of three analyses were presented at the European Heart Rhythm Association (EHRA) EUROPACE-CARDIOSTIM 2017, June 18-21 in Vienna, Austria.

Findings from a European health-economic analysis demonstrated that treating patients with AdaptivCRT results in lower healthcare costs and extends life expectancy by an average of four months. The findings, which span three countries' healthcare systems, showed that lifetime costs for patients treated with AdaptivCRT were lower than for patients treated with traditional pacing algorithms:

 
With AdaptivCRT algorithm
Without AdaptivCRT algorithm

Italy
€28,113.00
€29,215.16

Spain
€29,618.89
€30,833.93

United Kingdom
€29,425.37 (£25,454.47)
€30,273.19 (£26,274.39)

The AdaptivCRT algorithm is available in the Medtronic Claria MRI Quad CRT-D SureScan, Amplia MRI Quad CRT-D SureScan, Percepta Quad CRT-P MRI SureScan and Serena Quad CRT-P MRI SureScan systems. It adjusts the way the device paces the heart according to minute-to-minute evaluations of each patient's rhythm, and leads to improved outcomes through reducing patients' odds of a 30-day heart failure readmission and their risk of developing AF.

A second analysis — from the prospective, randomized CRTee study — showed that the Medtronic device-based EffectivCRT during AF algorithm improved effective left ventricular pacing by 19 percent (87±16 percent vs. 68 ± 37 percent; p<0.001) in patients with AF, compared to devices without the technology.

"It is exciting to see that this technology helps increase the amount of CRT delivered during atrial fibrillation," said Giuseppe Boriani, M.D., Ph.D., full professor of cardiology at the University of Modena and Reggio Emilia, Italy. "Many patients with heart failure experience AF at some point, and we now have the ability to better address the individual needs of these difficult-to-treat patients."

AF is one of the most common heart rhythm disorders. It involves an irregular quivering or rapid rhythm in the heart's upper chambers. A large percentage of heart failure patients receiving CRT also have AF, which can significantly reduce patient response to the therapy. The EffectivCRT Diagnostic, exclusive to the Medtronic Claria CRT-D and Percepta CRT-P devices, automatically determines the effectiveness of left ventricular pacing, and the EffectivCRT during AF algorithm automatically adjusts pacing rates during AF.

Finally, the latest economic analysis of Medtronic CRT-defibrillators (CRT-D) demonstrated a highly significant increase in projected device longevity: up to nine  years for Claria and Amplia devices, and 8.1 years in Viva XT CRT-Ds, which are substantial improvements compared to predecessor models.

"By improving device longevity, there are substantially fewer device replacements and, in turn, significant cost savings and fewer procedure-related complications," said Haran Burri, M.D., Ph.D., associate professor of cardiology at the University Hospital of Geneva, Switzerland.

For more information: www.medtronic.com

Related Content

Surgery Could Reduce Frailty in Adults With Heart Failure
News | Heart Failure| November 17, 2017
November 17, 2017 — Common practice, and recently published research, shows that the risk of complications with surge
News | Antiplatelet and Anticoagulation Therapies| November 16, 2017
Bristol-Myers Squibb Company and Pfizer Inc. released real-world data (RWD) of outcomes associated with direct oral...
SPRINT Trial Data Support New AHA/ACC Hypertension Guidelines
News | Hypertension| November 16, 2017
Findings from a landmark study funded by the National Institutes of Health (NIH) support a key component of the new...
Videos | FFR Technologies| November 15, 2017
A discussion with William Fearon, M.D.
Philips Azurion Image-Guided Therapy Platform Improves Clinical Workflow for Interventional Procedures
News | Angiography| November 15, 2017
Philips announced the results of a comprehensive, independent, two-year study demonstrating the clinical workflow...
Videos | Heart Valve Technology| November 15, 2017
Ted Feldman, M.D., MSCAI FACC FESC, director of the cardiac cath lab, Evanston Hospital, is the principal investigato
Videos | Left Atrial Appendage (LAA) Occluders| November 14, 2017
Vivek Reddy, M.D., director of cardiac arrhythmia services and professor of medicine, cardiology, Mount Sinai Hospita
Mexican Doctors Safely Reuse Donated Pacemakers After Sterilization
News | Pacemakers| November 10, 2017
Mexican doctors have safely reused donated pacemakers after sterilization, shows a study presented at the 30th Mexican...
TCT 2017 late-breaking trials and studies that will be presented on the latest cardiology technology clinical trials.
Feature | TCT| November 09, 2017
November 9, 2017 — From numerous high-quality submissions, Transcatheter Cardiovascular Therapeutics (TCT) has select
Overlay Init